Potent and highly selective antagonist of the orexin 1 receptor (Ox1R)

More than 1,000 fold selective for Ox1R versus other therapies to achieve efficacy without somnolence

Orexin-1 Receptor

Localized on the locus coeruleus (LC) controlling noradrenergic neurotransmission and the reward pathways of the VTA / NAc.

Key brain structures involved in regulating mood, motivation and behavior.

Dysfunctional in psychiatric disorders, such as schizophrenia and anxiety.

Orexin-2 Receptor

Preferentially localized in the histaminergic tuberomamillary nucleus (TMN).

Controls arousal and wakefulness.

Orexin 2 receptor modulators targeted for sleep indications (e.g., suvorexant).

orexin-1 and 2 recpetor comparison

The most common adverse effects of other Ox1R antagonists, which have lower levels of selectivity, include somnolence and fatigue. In the Phase 1 study, there was no increase of somnolence or fatigue in subjects dosed with CVN766 versus placebo, potentially demonstrating a benefit of CVN766 over other Ox1R antagonists.


CVN766 Adverse events on the SAD study
CVN766 Adverse Events for MAD study

Psychiatric Conditions

CVN766 is a potent antagonist of the orexin 1 receptor with high selectivity over the orexin 2 receptor which may benefit a variety of psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome.